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Abstract 
Objective: The objective of the study was to investigate whether clinically used ultrasonic 
contrast agents improved the accuracy of spectral Doppler ultrasound in the detection of low 
grade (< 50%) renal artery stenosis.  Low grade stenoses in the renal artery are notoriously 
difficult to reliably detect using Doppler ultrasound due to difficulties such as overlying fat and 
bowel gas.   
Methods: A range of anatomically-realistic renal artery phantoms with varying low degrees of 
stenosis (0, 30 and 50%) were constructed and peak velocity data was measured from within 
the pre-stenotic and mid-stenotic regions in each phantom, for both unenhanced and contrast-
enhanced spectral Doppler data acquisitions.  The effect of a 20mm overlying fat layer on the 
ultrasound beam distortion and phase aberration, and hence on the measured peak velocity 
data, was also investigated.   
Results: The overlying fat layer produced a statistically significant underestimation (p<0.01) in 
both the peak velocity and peak velocity ratio [Stenotic Region(Vmax)/Pre-stenotic 
Region(Vmax)] for the 0% and 30% stenosis models, but not the 50% model.  A statistically 
significant increase (p<0.01) in the peak velocity was found in the contrast-enhanced Doppler 
spectra; however, no significant difference was found between the unenhanced and contrast 
enhanced peak velocity ratio data, which suggests that the ratio metric has better diagnostic 
accuracy.  The peak velocity ratios determined for each of the contrast-enhanced phantoms 
correctly predicted if the phantom had a stenosis and furthermore correctly classified the 
degree of stenosis.   
Conclusion: Contrast-enhanced Doppler ultrasound could significantly assist in the early 
detection of renal artery disease. 
Highlights 
 Anatomically realistic flow phantoms  
 Contrast-enhanced Doppler spectra 
 Fat Mimicking layers  
KEY WORDS: Doppler Ultrasound; Ultrasound Contrast Agents; Anatomical Renal Artery 
Phantoms; Peak Velocity; Peak Velocity Ratio. 
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Introduction 1 
Renal artery stenosis (RAS) is the most common cause of potentially curable secondary 2 
hypertension, with the most frequent cause being due to atherosclerosis (63 %) in patients 3 
older than 50 years and fibromuscular dysplasia (32 %) in younger patients.  Secondary 4 
hypertension is potentially curable, and so its early detection is critical as this offers the 5 
possibility of noninvasive antihypertensive drug treatments rather than more invasive 6 
procedures such as re-vascularization through percutaneous transluminal renal angioplasty or 7 
surgery [1-5].  If left untreated, this progressive disease has many associated morbidities 8 
including renal insufficiency, myocardial infarction, congestive heart failure, stroke and death.  9 
Consequently, there is significant interest in the detection of atherosclerotic disease in the 10 
renal artery and whether more accurate stenosis assessment techniques would improve patient 11 
outcome [6].  Ultrasound is considered to be an ideal first-line imaging technique for RAS due to 12 
the fact that it is non-ionizing, non-invasive, of low cost [7-9] and in this regard, it is a promising 13 
technique for RAS detection, specifically duplex ultrasound (DUS), which combines the direct 14 
visualization of the renal arteries via B-mode imaging with Doppler measurement of the 15 
velocity of blood flow in the main renal artery and within the kidney [10, 11].  In comparison 16 
with the “gold standard” technique of X-ray Intra-Arterial Digital Subtraction Angiography (IA-17 
DSA), which has a sensitivity of 94-100% and specificity of 65-97% for RAS detection, DUS has a 18 
sensitivity of 67–98% and a specificity of 54–99% [6-8, 11-14]. DUS has several limitations, 19 
including its dependence on the skill of the operator, its ability to visualize accessory renal 20 
arteries, its determination of high velocities at depth without aliasing, and a lack of Doppler 21 
measurement sensitivity when imaging obese patients and those with overlying bowel gas [9, 22 
15].  However, with an experienced operator, Duplex ultrasound has been found to be reliable 23 
[16].  24 
 25 
Ultrasound microbubble contrast agents are routinely used in contrast enhanced harmonic 26 
imaging for enhancing the visibility of the arterial system, and have been found to enhance the 27 
Doppler signal thereby, improving the diagnostic capability for RAS grading where the signal can 28 
be affected by overlying fat layers [17]. Specifically, the use of ultrasound microbubble contrast 29 
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agents were found to increase the number of examinations which were deemed to be 30 
diagnostic in multicenter studies [18, 19].  This improvement in the diagnostic efficacy was 31 
found to aid the operator’s ability to visualize the anatomy of the renal arteries, thereby 32 
decreasing the number of inadequate Doppler studies [18]. However, several studies which 33 
investigated the effect of ultrasound contrast agents on the measured spectral Doppler 34 
velocities, both in vitro and in vivo, reported conflicting results regarding an artificial increase in 35 
the peak systolic velocity due to the contrast agent itself [20-22].   36 
 37 
 38 
Furthermore, it has been found in simple flow phantom in-vitro experiments that the presence 39 
of an overlying fat layer can result in underestimation of the peak velocity measurement, 40 
leading to a consequent incorrectly classified severity of stenosis.  Given the physiology of the 41 
body, particularly in elderly patient populations, overlying subcutaneous fat layers are a 42 
common problem in renal artery imaging, and their impact can be confounded if the PSV 43 
parameter alone is used to classify the severity of a stenosis, thereby negatively impacting the 44 
patient’s management and treatment [23].  The aim of this study was to perform a systematic 45 
investigation of the effect of an overlying fat layer on Doppler measurements of Peak Velocity 46 
and Peak Velocity Ratio using two commercially-available contrast agents, using anatomically 47 
realistic renal artery flow phantoms with varying degrees of accurately-known stenosis. 48 
 49 
Methodology  50 
Phantom Design and Manufacture 51 
The vessel geometry used to fabricate the range of wall-less anatomically realistic renal artery 52 
flow phantoms was developed using inverse casting of a physical model produced by a rapid 53 
prototyping machine, based on a clinical 3-D X-ray computed tomography dataset of a healthy 54 
renal artery where the renal artery lumen diameter was measured to be 6.7 mm [24]. The 55 
vessels were manufactured by means of a silicone inverse mould which had a non-stenotic 56 
diameter equal to the lumen diameter of the renal artery (7.7 mm), using a methodology 57 
described previously [24].  The difference in the in dimensions of the final renal artery lumen 58 
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was as a result of the rapid prototyping process that resulted in the model diameter increasing 59 
by approximately 1 mm.  An agar-based tissue mimicking material (TMM) was used in the flow 60 
phantoms [25].  Its composition and manufacture have previously been described by [26] and 61 
has been acoustically characterised and found to have good acoustic reproducibility between 62 
batch production [27-31].  The wall-less flow phantoms were attached to a flow circuit at the 63 
inlet and the outlet using 7.9 mm inner diameter Nalgene PVC plastic tubing (Thermo Fisher 64 
Scientific, NY, USA).  The flow circuit consisted of blood mimicking fluid (BMF) pumped through 65 
the anatomical flow phantom by a high flow rate suction-shoe pump (07002-23, Cole-Parmer, 66 
Walden, UK) coupled to a direct-current servo motor (McLennan Servo Suppliers Ltd., Surrey, 67 
UK); a schematic of the circuit is shown in Figure 1.  The BMF, which incorporated orgasol 68 
particles to replicate the red blood cells, has been previously characterised to have acoustic and 69 
physical properties similar to that of human blood [32].  An injection port, attached to a syringe 70 
via a 3-way tap, was inserted and glued into the plastic tubing, 22 cm from the inlet of the 71 
phantom and downstream from the pump for the injection of the contrast agents.  Finally, a 20 72 
mm scanning well of either speed-of-sound-corrected water or olive oil layer (i.e. a fat-73 
mimicking layer, representing the fat layer in an average patient) [23, 33, 34] was coupled to 74 
the surface of each of the flow phantoms. The transducer was positioned longitudinally over 75 
the vessel and held in place using a clamp attached to a micrometer manipulator on a 76 
translation stage.  The transducer was held at an angle,  = 30°, to the surface of the scanning 77 
well and the total distance from the face of the transducer to the center of the unstenosed 78 
vessel was 82 mm (representing the depth of the renal artery in the average patient) [34], as 79 
can be seen in Figure 1.  80 
The motor was driven by a servo amplifier (Aerotech Ltd, Berkshire, UK), multifunctional I/O 81 
board (PCI-6036E National Instruments, Austin, TX, USA) and a computer controller program 82 
developed in LABVIEW (National Instruments, Austin, TX, USA) was used to output a steady-83 
state mean velocity of 26 cm s-1 which was used for all measurements.  The steady-state mean 84 
velocities output by the pump system was calibrated using timed weight collection.  It was 85 
important to ensure that the flow was laminar; therefore, the tube was straightened to an inlet 86 
length of 26 cm, as determined by:  L = 0.04 dRe, where L=inlet length, d = diameter and Re = 87 
 6 
 
Reynolds number, for a maximum velocity of 40 cm s-1 and BMF with a viscosity of 4 mPa s-1. 88 
The temperature of the flow phantom and BMF was maintained at 22  1 oC throughout.  89 
 90 
Three different stenosis phantoms were used: 0% (normal, un-stenosed), 30% stenosis and 50% 91 
stenosis (diameter reduction determined the stenosis, as shown in Figure 2.  The stenosis were 92 
placed 10 mm from the inlet end of the phantom as it has been found that 60% of renal artery 93 
stenosis have been shown to occur at this point [35].  The centre of the vessel was located at a 94 
depth of 62 mm below the surface of the TMM phantom, representing the depth of the renal 95 
artery in the average patient [34]. 96 
 97 
Contrast Agents 98 
Two contrast agents were used in this study: SonoVueTM (Bracco, Italy) and LUMINITY®   99 
(Lantheus Medical Imaging, USA). Both agents were reconstituted immediately prior to 100 
experiments and were discarded after a period of 4 hours to ensure consistency of the 101 
microbubbles used in the experiments. The agents were diluted in saline to a concentration of 102 
1:1000, and 5 ml of the diluted contrast solution was injected manually over 2 s via the 103 
injection port described above.  For each of the experiments, a comparison was made between 104 
the non-enhanced and contrast-enhanced Doppler spectra obtained from the BMF flowing 105 
through the phantom. For the contrast experiments, the BMF was not recirculated. 106 
 107 
Measurements 108 
An ATL HDI 3000 (Philips Medical Systems, Bothwell, WA, USA) ultrasound system with a 109 
broadband curvilinear transducer C4-2 (nominal frequency 2.5 MHz) was used to collect the 110 
peak velocity data in each of the anatomically-realistic renal artery flow phantoms.  Peak 111 
velocity measurements (Vmax) were acquired at both the pre-stenotic and mid-stenotic regions 112 
within each of the phantoms, and from these measurements the peak velocity ratio [Stenotic 113 
Region(Vmax) / Pre-stenotic Region(Vmax)] was determined.  The transducer was positioned 114 
longitudinally over the region of interest and held in place using a clamp attached to a 115 
micrometer manipulator on a translation stage which translated the transducer between the 116 
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two positions.  The focal zone was positioned in the centre of the vessel and the time gain 117 
compensation control was adjusted to produce a uniform image of the TMM of the phantom.  118 
Spectral Doppler was turned on and Doppler velocity measurements were recorded with a gate 119 
length of 7.5 mm, the same diameter as the vessel lumen and the depth of the gate length was 120 
82 mm (Figure 2).  The following settings were used throughout the study.  The pulse repetition 121 
frequency was adjusted so that the measured maximum flow velocity (without contrast) was no 122 
greater than 75% of the maximum spectral display to minimise the effect of Doppler aliasing. 123 
The wall filter was set to the lowest setting. The transducer was manually positioned to give a 124 
Doppler angle of 60o, as typically used clinically.  The mechanical index was set to 0.1 and the 125 
Doppler gain was adjusted to 66% to obtain a strong Doppler waveform which was free from 126 
extraneous noise as determined prior to contrast agent administration.  Doppler recording was 127 
continued without change in position of the range gate or ultrasound machine settings (such as 128 
gain, wall filter and transmit power) throughout the contrast effect.  The goal was to make 129 
uninterrupted Doppler recordings throughout the contrast effect [22].     130 
A cine-loop of the Doppler waveform was obtained. This was repeated three times for each of 131 
the renal artery flow phantoms (0%, 30%, 50%), at both pre-stenotic and mid-stenotic 132 
positions, for each contrast agent and for both the water and oil baths (36 Doppler spectra data 133 
sets). One observer, who was not blinded to the study, manually undertook the measurement 134 
of the peak velocities and peak velocity ratios from each of the spectra obtained (n=4 135 
measurements at each site) for peak-enhancement and post-enhanced of the contrast 136 
agent.Statistical analyses was carried out using a dedicated software (SPSS, IBM, Armonk, NY, 137 
USA). Independent sample t-tests were used to compare (1) the Doppler measurement with no 138 
contrast agent with the water and oil layers and (2) the Doppler measurement with no contrast 139 
agent and the two types of contrast agents with the water and oil layers. 140 
 141 
 142 
Results 143 
The effect of the overlying oil layer on the accuracy of peak velocity estimations was 144 
determined for each of the anatomically renal artery flow phantoms and the results are 145 
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presented in Table 1.  A statistically significant underestimation in the peak velocity was 146 
measured for the 0% and 30% stenosis models (p < 0.01), while no difference was found for the 147 
50% stenosis model. The effect of the overlying oil layer on the peak velocity ratio was 148 
determined and found to be underestimated when there was an overlying oil layer in all three 149 
of the anatomically realistic models; these results for the un-enhanced data are also presented 150 
in Table 1.  It can be seen from Figure 3 (a) – (b) that the overall brightness of the B-mode 151 
image and the Doppler spectrum were decreased due to the increased attenuation of the 152 
overlying oil layer.      153 
 154 
The effect of both commercially-available contrast agents on the measured peak velocity in the 155 
absence and presence of an overlying oil layer was determined for each of the anatomically 156 
realistic renal artery flow phantoms and the results are presented in Figure 4 (a) – (c).  No 157 
significant difference was measured in the peak velocity measurements with the overlying oil 158 
layer for both LUMINITY® and SonoVueTM, compared to the underestimation produced by the 159 
oil layer in the absence of a contrast agent, for each of the renal artery flow phantom models.  160 
This demonstrates the improvement in the diagnostic accuracy in the challenging imaging 161 
situation presented by the overlying oil layers, with the administration of the contrast agents.  162 
The measured peak velocities increased between 9 – 20% in each of the renal artery flow 163 
phantom models following the administration of both LUMINITY® and SonoVueTM compared to 164 
the unenhanced control peak velocity measurements for the BMF.   165 
 166 
The data for the peak velocity ratios are presented in Figure 5. In general, it can be seen that 167 
the spectra with no oil layer had a higher peak velocity ratio compared with the spectra which 168 
were attenuated by the overlying oil layer, for conditions of no contrast agent and with both 169 
LUMINITY® and SonoVueTM, at 50% stenosis and normal renal artery flow phantom models, 170 
respectively.  There was no significant difference between the peak velocity ratios for the 171 
unenhanced and enhanced measured ratios, which suggests that the ratio has better diagnostic 172 
accuracy.  All the peak velocity ratios determined for each of the renal artery flow phantoms 173 
correctly predicted if the phantom had a stenosis as well as correctly classifying the degree, 174 
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except for the unenhanced 50% stenosis in the presence of an overlying oil layer.  For this 175 
spectrum the peak velocity ratio was underestimated.  176 
 177 
Discussion 178 
Renal artery imaging is regarded as technically challenging due to the overlying subcutaneous 179 
fat of larger patients and/or in the presence of bowel gas and the corresponding reduction in 180 
the Doppler signal [6].  Previous studies have found that the presence of overlying fat layers can 181 
cause an underestimation in the measured peak velocity which could result in the patient being 182 
incorrectly managed or undertreated [23].  This current study corroborated this 183 
underestimation in the peak velocity, by up to 13% when a 20 mm overlying oil layer was 184 
present.  This underestimation is most likely due to: (i) the lower speed of sound within the oil 185 
layer, which causes a decrease in the peak velocity determined by the ultrasound system, and 186 
(ii) the additional attenuation, by the oil layer, of the higher Doppler shift frequencies, which 187 
further reduces the peak velocity determined by the ultrasound system.  Ultrasound contrast 188 
agents are known to enhance the amplitude of Doppler signals by increasing the amount of 189 
ultrasound beam energy being backscattered, and thus they can provide enhanced visualization 190 
of weak Doppler signals that are beyond the detection capabilities of the system due to 191 
excessive depth or attenuation [22, 36-38].  In particular, it may increase the detectability of 192 
weak low velocity signals at the edge of the vessel as well as higher velocities whose higher 193 
Doppler shift frequency would have been more preferentially attenuated due to the overlying 194 
fat layers.  Thus, in addition to investigating the effects of overlying fat layers, the current study 195 
further investigated the impact of ultrasound microbubble contrast agents on the measured 196 
peak velocity by providing greater enhancement of the blood mimicking fluid and the 197 
corresponding Doppler signal.  In studies where attenuation has been a feature affecting the 198 
Doppler signal, it has been found that there was no change in the measured peak velocity 199 
following the administration of ultrasound contrast agents [20, 22]; specifically, Guberlet et al, 200 
found no enhancement in the measured peak systolic velocity in an in vitro study of human 201 
common carotid arteries [39].  In contrast a number of investigators have argued that there 202 
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was in fact an increase in peak velocity following the administration of contrast agents and it 203 
was proposed that the observed higher velocities represented real signals that were beyond 204 
the detection limits of the Doppler processing unit prior to the administration of the contrast 205 
agent [21].  Forsberg et al. argued that this increase was not artificial, but rather is real signal 206 
deriving from the relatively small number of red blood cells moving at the highest velocity in 207 
the vessel, which prior to the injection of the contrast agent went undetected [40]. 208 
These findings were specific to the contrast agent Levovist (Bayer Shering), and the 209 
characterization of this potential effect for other contrast agents was not addressed.  In the 210 
current study, it was demonstrated definitively that that the measured peak velocity increased 211 
significantly following the administration of two commercially-available contrast agents, 212 
SonoVueTM (Bracco) and LUMINITY® (Lantheus Medical Imaging) compared to the unenhanced 213 
Doppler spectra.  214 
The impact of the overlying fat layer on the PSV measurements was reduced with the 215 
administration of both types of contrast agents.  In particular it was found that the PSVs in the 216 
absence and presence of the fat mimicking layer were comparable which is most likely due to 217 
the limited Doppler sensitivity and detection without the contrast agents of the weaker Doppler 218 
signals of the maximum velocity.  There was no significant difference between the PSV 219 
measured in the 50 % stenosis in the absence and presence of the fat mimicking layer this could 220 
be due to the increased magnitude of red blood cells travelling at this maximum velocity in the 221 
local stenosed region whereas in the normal and 30 % stenosed renal artery phantom in 222 
presence of fat the signal amplitude of the PSV was lower due to firstly, the attenuation of the 223 
fat mimicking layer and secondly, the lower signal magnitude of the increased PSV of the non-224 
haemodynamically significant stenosis.  With both of these factors combine the increased PSV 225 
may have been beyond the Doppler detection of system. This requires further investigation as it 226 
was expected that the PSV would be underestimated in a similar manner as it was in the normal 227 
and 30 % stenosis renal artery flow phantom in the presence of the fat mimicking layer. 228 
 229 
All the peak velocity ratios determined for each of the renal artery flow phantoms correctly 230 
predicted the degree of stenosis present in the anatomically realistic flow phantom for the 231 
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unenhanced and enhanced Doppler spectra.  For this latter spectrum, the peak velocity ratio 232 
was underestimated, which in a clinical situation has the potential to negatively affect the 233 
patient management. However, with the application of contrast agents, this degree of stenosis 234 
was correctly predicted, with increased peak velocity and peak velocity ratio measured.  The 235 
use of the RAR instead of the absolute PSV value is preferable where the existence of 236 
hypertension is suspected as this can cause increased PSV velocities in all the vessels in 237 
hypertensive patients [19] It has been found in multiple studies that an RAR of > 3 successfully 238 
identified hemodynamically significant lesions with a sensitivity and specificity of 91 - 92% and 239 
77 - 91%, respectively [19].  However, Doppler examinations were prone to technical failure in 240 
due to severe obesity, the use of older US devices, excessive bowel gas or poor flow in the main 241 
RA due to severe renal impairment.  Therefore, the overlying fat layer may have been the 242 
reason as to why the RAR measured in the renal artery with a 50 % was < 2.  Furthermore, the 243 
two stenoses evaluated in this study would be regarded as early disease as well as not being 244 
considered as haemodynamically significant (> 60 %).  With the use of ultrasound contrast 245 
agents it can be seen that the presence of that both of these lower grade stenoses were 246 
differentiated using the RAR parameter from the normal renal artery.   247 
 248 
Finally, the use of the two commercially-available contrast agents improved the delineation of 249 
the vessel, thereby improving the diagnostic accuracy of the Doppler examination, particularly 250 
in the presence of a fat mimic layer which produced a weaker spectrum with lower signal-to-251 
noise ratio and affected the measured unenhanced peak velocity.    252 
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Conclusion 253 
A range of anatomically-realistic renal artery flow phantoms with varying degrees of stenosis 254 
were used to investigate the effect of a bolus injection of two commercially-available contrast 255 
agents, SonoVueTM (Bracco) and LUMINITY® (Lantheus Medical Imaging).  It was found that the 256 
peak velocity measured by Doppler ultrasound increased following the bolus injection of both 257 
contrast agents, with no significant difference observed between the contrast agents. All the 258 
peak velocity ratios determined for each of the renal artery flow phantoms correctly predicted 259 
the degree of stenosis present in the anatomically realistic flow phantom for the unenhanced 260 
and enhanced Doppler spectra, except for the unenhanced 50% stenosis in the presence of a 261 
fat-mimicking overlying oil layer.  For this latter spectrum, the peak velocity ratio was 262 
underestimated, which could potentially negatively affect the patient management. However, 263 
with the administration of either contrast agent, this degree of stenosis was correctly 264 
predicted, indicating that the use of contrast agents improved the diagnostic accuracy of the 265 
Doppler examination.  Furthermore, the two stenoses evaluated in this study would be 266 
regarded as early disease as well as not being considered as haemodynamically significant (> 267 
60 %).  With the use of ultrasound contrast agents it can be seen that the presence of that both 268 
of these lower grade stenoses were differentiated using the RAR parameter from the normal 269 
renal artery.  This work would suggest that the use of contrast agents may well become an 270 
essential tool for the clinician in the diagnosis of low grade stenosis in an increasing overweight 271 
and obese population.  In conclusion, the use of ultrasound contrast agents could provide 272 
information at an earlier stage of disease progression which can be incorporated into a 273 
stratified screening program for higher risk patient groups (such as diabetic patient groups).  274 
This could be used to positively alter patient outcomes, specifically provide earlier drug 275 
treatment interventions and possibly delay the loss of kidney function and the need for kidney 276 
transplant or haemodynamic dialysis.   277 
  278 
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 283 
Figure 1. Schematic of the flow circuit used for the renal artery contrast-enhanced flow 284 
phantom measurements 285 
 286 
Figure 2: (a) Illustration of the method used to determine the degree of stenosis; (b) 287 
Photograph of the 0%, 30% and 50% stenosis models; and (c) ultrasound image and Doppler 288 
spectrum for the 50% stenosis renal artery flow phantom.  289 
 290 
 291 
Figure 3: The top row shows the Doppler Spectrum measured in the 50% stenosis renal artery 292 
flow phantom at the point of the stenosis with the 20 mm overlaying water layer (left) and 20 293 
mm overlaying fat mimicking olive oil layer (right).   294 
 295 
Figure 4: Peak Velocity measurements at the point of the stenosis in (a) 0% (normal, 296 
unstenosed); (b) 30% stenosis and (c) 50% stenosis renal artery flow phantom unenhanced and 297 
with peak enhancement following administration of the commercially-available contrast agents 298 
LUMINITY® and SonoVueTM, with a 20 mm water layer and a 20 mm fat-mimicking olive oil 299 
layer.  300 
 301 
Figure 5: Peak Velocity Ratio measurements at the point of the stenosis in (a) 0% (normal, 302 
unstenosed); (b) 30% stenosis and (c) 50% stenosis renal artery flow phantom unenhanced and 303 
with peak contrast enhancement following administration of the commercially-available 304 
contrast agents LUMINITY® and SonoVueTM with a 20 mm water layer and a 20 mm fat 305 
mimicking olive oil layer.  The normal peak velocity ratio is indicated by the red line and the 306 
50% stenosis is indicated by the blue line. 307 
 308 
Table 1.  The peak velocity (Vmax) and Peak Velocity ratio [Stenotic Region(Vmax)/Pre-stenotic 309 
Region(Vmax)] measured at the site of stenosis at a set mean steady velocity of 26 cm s
-1 in the 310 
0%, 30% and 50% stenosed renal artery flow phantom with the scanning well filled with speed 311 
of sound corrected water and the olive oil fat mimic.  312 
 313 
 314 
  315 
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Figure 1. Schematic of the flow circuit used for the renal artery contrast-enhanced flow 
phantom measurements 
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Figure 2: (a) Illustration of the method used to determine the degree of stenosis; (b) 
Photograph of the 0%, 30% and 50% stenosis models; and (c) ultrasound image and Doppler 
spectrum for the 50% stenosis renal artery flow phantom.  
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Figure 3: Doppler Spectrum measured in the 50% stenosis renal artery flow phantom at the 
point of the stenosis with the 20 mm overlaying water layer (left) and 20 mm overlaying fat 
mimicking olive oil layer (right).  
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Figure 4: Peak Velocity measurements at the point of the stenosis in (a) 0% (normal, 
unstenosed); (b) 30% stenosis and (c) 50% stenosis renal artery flow phantom unenhanced 
(n=12) and with peak enhancement following administration of the commercially-available 
contrast agents LUMINITY® (n=12) and SonoVueTM (n=12), with a 20 mm water layer and a 
20 mm fat-mimicking olive oil layer.  
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Figure 5: Peak Velocity Ratio measurements at the point of the stenosis in (a) 0% (normal, 
unstenosed); (b) 30% stenosis and (c) 50% stenosis renal artery flow phantom unenhanced 
(n=12) and with peak contrast enhancement following administration of the commercially-
available contrast agents LUMINITY® (n=12) and SonoVueTM (n=12) with a 20 mm water layer 
and a 20 mm fat mimicking olive oil layer.  The normal peak velocity ratio is indicated by the red 
line and the 50% stenosis is indicated by the blue line. 
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Table 1.  The peak velocity (Vmax) and Peak Velocity ratio [Stenotic Region(Vmax)/Pre-stenotic 
Region(Vmax)] measured at the site of stenosis at a set mean steady velocity of 26 cm s
-1 in the 
0%, 30% and 50% stenosed renal artery flow phantom with the scanning well filled with speed 
of sound corrected water and the olive oil fat mimic.  
 
Stenosis Scanning 
Well 
Vmax 
(cm s-1) 
[% difference] 
Peak Velocity 
ratio 
 
 
Normal 
 
No oil 
Oil  
70 ± 2.5 
60 ± 2.5 
[-13]† 
1.3 
1.0 
 
30% 
 
No oil 
Oil  
98 ± 2.5 
92 ± 2.5 
[-6]† 
1.7 
1.5 
 
50% No oil 
Oil  
109 ± 2.5 
109 ± 2.5 
[No difference] 
2.2 
1.8 
 
† Statistically significant p < 0.01 
 
